Eli Lilly recently announced more findings suggesting that it’s rheumatoid arthritis drug called baricitinib could improve the condition of patients with severe SARS-CoV-2 infections while used in combination with Gilead Science’s antiviral drug remdesivir. The data was presented recently by John Beigel, MD, at the special International Society for Influenza and other Respiratory Virus Diseases Antiviral Group (isirv-AVG) Virtual Conference on Therapeutics for COVID-19.
These findings are part of additional efficacy and safety data from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Patients Needing Supplemental Oxygen Benefit
The study data reveals that the most prominent benefits were observed in patients requiring supplemental oxygen (grade 5 on the eight-point ordinal scale) and those who required high-flow oxygen/non-invasive ventilation (grade 6) at baseline.
Clarification and Elaboration on Findings
New data presented today provides a better understanding of the improved clinical outcomes in hospitalized adults with COV...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).